Literature DB >> 17937675

Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia.

J Visser1, H W Nijman, B-N Hoogenboom, P Jager, D van Baarle, E Schuuring, W Abdulahad, F Miedema, A G van der Zee, T Daemen.   

Abstract

Oncogenic human papillomavirus (HPV)-infection is crucial for developing cervical cancer and its precursor lesions [cervical intraepithelial neoplasia (CIN)]. Regulatory T cells (T(regs)) might be involved in the failure of the immune system to control the development of HPV-induced cancer. We investigated frequencies, phenotype and activity of T(regs) in patients with cervical neoplasia. CIN and cervical cancer patients showed increased CD4(+)/CD25(high) T cell frequencies in peripheral blood and CD4(+) T cell fraction. These CD4(+)/CD25(high) T cells represent T(regs) as demonstrated by their low proliferation rate, low interferon (IFN)-gamma/interleukin (IL)-10 ratio, high expression of CD45RO, GITR, CTLA-4, forkhead box P3 (FoxP3) and low CD45RA expression. Moreover, in HPV16(+) cervical cancer patients, in-vitro depletion of CD25(+) T cells resulted in increased IFN-gamma T cell responses against HPV16 E6- and E7 peptides. Thus, increased frequencies of T(regs) in cervical cancer patients may indeed suppress HPV-specific immunity. Longitudinal analysis of CD4(+)/CD25(high) T cell frequencies in patients showed a modest decline 1 year after curative surgery or chemoradiation. This study demonstrates increased frequencies and suppressive activity of T(regs) in cervical cancer. These results imply that T(regs) may suppress the immune control of cervical neoplasia and furthermore that suppression of immunity by T(regs) will be another hurdle to overcome in therapeutic immunization strategies against cervical neoplasia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17937675      PMCID: PMC2219359          DOI: 10.1111/j.1365-2249.2007.03468.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.

Authors:  Noelia Casares; Laura Arribillaga; Pablo Sarobe; Javier Dotor; Ascensión Lopez-Diaz de Cerio; Ignacio Melero; Jesús Prieto; Francisco Borrás-Cuesta; Juan J Lasarte
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

2.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

3.  POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women.

Authors:  Nicole W J Bulkmans; Lawrence Rozendaal; Peter J F Snijders; Feja J Voorhorst; A Joan P Boeke; Gladys R J Zandwijken; Folkert J van Kemenade; René H M Verheijen; Krijn v Groningen; Mathilde E Boon; Hans J F Keuning; Marjolein van Ballegooijen; Adriaan J C van den Brule; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2004-05-20       Impact factor: 7.396

4.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

5.  Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection.

Authors:  Akiko Kobayashi; Ruth M Greenblatt; Kathryn Anastos; Howard Minkoff; Leslie S Massad; Mary Young; Alexandra M Levine; Teresa M Darragh; Vivian Weinberg; Karen K Smith-McCune
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

6.  Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.

Authors:  Annemieke de Jong; Mariëtte I E van Poelgeest; Jeanette M van der Hulst; Jan Wouter Drijfhout; Gert Jan Fleuren; Cornelis J M Melief; Gemma Kenter; Rienk Offringa; Sjoerd H van der Burg
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

7.  Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment.

Authors:  Jenny C Luxton; Rahul Nath; Nawal Derias; Amanda Herbert; Philip S Shepherd
Journal:  J Gen Virol       Date:  2003-05       Impact factor: 3.891

8.  Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients.

Authors:  Andrea Fattorossi; Alessandra Battaglia; Gabriella Ferrandina; Alessia Buzzonetti; Francesco Legge; Vanda Salutari; Giovanni Scambia
Journal:  Gynecol Oncol       Date:  2004-01       Impact factor: 5.482

9.  Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens.

Authors:  Einar M Aandahl; Jakob Michaëlsson; Walter J Moretto; Frederick M Hecht; Douglas F Nixon
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma.

Authors:  Andrea Fattorossi; Alessandra Battaglia; Gabriella Ferrandina; Ferdinando Coronetta; Francesco Legge; Vanda Salutari; Giovanni Scambia
Journal:  Cancer       Date:  2004-04-01       Impact factor: 6.860

View more
  25 in total

1.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

2.  Alterations of T-cell surface markers in older women with persistent human papillomavirus infection.

Authors:  Ana Cecilia Rodríguez; Alfonso J García-Piñeres; Allan Hildesheim; Rolando Herrero; Matthew Trivett; Marcus Williams; Ivannia Atmella; Margarita Ramírez; Maricela Villegas; Mark Schiffman; Robert Burk; Enrique Freer; José Bonilla; Concepción Bratti; Ligia A Pinto
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

3.  Cross-sectional associations between cutaneous viral infections and regulatory T lymphocytes in circulation.

Authors:  S S Hampras; M Tommasino; Y Zhao; J L Messina; A R Giuliano; N A Fenske; B Cherpelis; R S Hesterberg; A A Akuffo; R P Amorrortu; J Balliu; L Vijayan; T Gheit; P K Epling-Burnette; D E Rollison
Journal:  Br J Dermatol       Date:  2019-02-10       Impact factor: 9.302

4.  Immunosuppressive tumor microenvironment in cervical cancer patients.

Authors:  Sytse J Piersma
Journal:  Cancer Microenviron       Date:  2011-05-31

Review 5.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

6.  High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women.

Authors:  Emmanouil Papasavvas; Lea F Surrey; Deborah K Glencross; Livio Azzoni; Jocelin Joseph; Tanvier Omar; Michael D Feldman; Anna-Lise Williamson; Maureen Siminya; Avril Swarts; Xiangfan Yin; Qin Liu; Cynthia Firnhaber; Luis J Montaner
Journal:  Oncoimmunology       Date:  2016-01-19       Impact factor: 8.110

7.  Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3.

Authors:  Mark E Scott; Yifei Ma; Lili Kuzmich; Anna-Barbara Moscicki
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

8.  Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy.

Authors:  Félix Giovanni Delgado; Elizabeth Martínez; María Angélica Céspedes; María Mercedes Bravo; María Cristina Navas; Alba Lucía Cómbita Rojas
Journal:  Immunology       Date:  2008-09-05       Impact factor: 7.397

9.  Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer.

Authors:  Marcus C B Tan; Peter S Goedegebuure; Brian A Belt; Brian Flaherty; Narendra Sankpal; William E Gillanders; Timothy J Eberlein; Chyi-Song Hsieh; David C Linehan
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

10.  Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways.

Authors:  Yi-Lan Zhang; Jiang Li; Hao-Yuan Mo; Fang Qiu; Li-Min Zheng; Chao-Nan Qian; Yi-Xin Zeng
Journal:  Mol Cancer       Date:  2010-01-10       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.